Edwards Lifesciences Files 8-K for Financial Updates

TL;DR

EDWARDS LIFESCIENCES FILED AN 8-K ON 7/24/24 - FINANCIALS AND OPERATIONS UPDATE.

AI Summary

Edwards Lifesciences Corporation filed an 8-K on July 24, 2024, to report on its results of operations and financial condition, as well as other events and Regulation FD disclosures. The filing pertains to the company's ongoing business operations and financial reporting.

Why It Matters

This filing provides crucial updates on Edwards Lifesciences' financial performance and operational status, which can influence investor decisions and market perception.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.

Key Players & Entities

• Edwards Lifesciences Corporation (company) — Registrant
• July 24, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of incorporation
• Irvine, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $1.00 — ich registered Common Stock, par value $1.00 per share EW New York Stock Exchange
• $1.2 billion — upfront purchase price of approximately $1.2 billion in cash at the closing of these acquisi
• $445 million — acquisitions, plus up to an additional $445 million upon the achievement of certain milesto

Filing Documents

• ew-20240724.htm (8-K) — 43KB
• ex-991q22024.htm (EX-99.1) — 631KB
• ex-992q22024.htm (EX-99.2) — 14KB
• ew45percentblacklrga211a.jpg (GRAPHIC) — 625KB
• ew45percentblacklrga21a.jpg (GRAPHIC) — 625KB
• 0001099800-24-000069.txt ( ) — 2568KB
• ew-20240724.xsd (EX-101.SCH) — 2KB
• ew-20240724_lab.xml (EX-101.LAB) — 21KB
• ew-20240724_pre.xml (EX-101.PRE) — 12KB
• ew-20240724_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On July 24, 2024, Edwards Lifesciences Corporation, a Delaware corporation ("Edwards"), issued a press release setting forth Edwards' financial results for the second quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended. Item7.01. Regulation FD Disclosure. On July 24, 2024, Edwards Lifesciences Corporation (the "Company") issued a press release announcing the Company has entered into an agreement to acquire JenaValve Technology, Inc. ("JenaValve"), a medical device company focused on the transcatheter treatment of aortic regurgitation. In the same press release, the Company also announced that it has exercised its option to acquire Endotronix, Inc. ("Endotronix"), a medical device company that recently received Premarket Approval from the U.S. Food and Drug Administration ("FDA") for its Cordella Sensor, an implantable pulmonary artery pressure sensor allowing early, targeted therapeutic intervention. A copy of the press release is attached as Exhibit 99.2 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.2, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item8.01. Other Events. In connection with the Company's acquisition of JenaValve and Endotronix, the Company

Forward-Looking Statements

Forward-Looking Statements This report includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements can sometimes be identified by the use of words such as "may," "will," "should," "anticipate," "believe," "plan," "project," "estimate," "potential," "predict," "expect," "intend," "guidance," "outlook," "optimistic," "aspire," "confident" or other forms of these words or similar expressions and include, but are not limited to, expectations regarding the completion of the Company's acquisitions of JenaValve and Endotronix, including the probability and price thereof. No inferences or assumptions should be made from statements of past performance, efforts, or results which may not be indicative of future performance or results. Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though they are inherently uncertain, difficult to predict, may be outside of the Company's control, and may be subject to the satisfaction of certain customary conditions. The Company's forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the Company does update or correct one or more of these statements, investors and others should not conclude that the Company will make additional updates or corrections. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include, but are not limited to: (i) the Company may be unable to close the acquisitions of each o

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated July 24, 2024, reporting Edwards' financial results for the second quarter of 2024. 99.2 Press release of Edwards Lifesciences Corporation, dated as of July 24, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 24, 2024 EDWARDS LIFESCIENCES CORPORATION By: /s/ Scott B. Ullem Scott B. Ullem Chief Financial Officer 4 Exhibit Index Exhibit Number Description 99.1 Press release, dated July 24, 2024, reporting Edwards' financial results for the second quarter of 2024. 99.2 Press release of Edwards Lifesciences Corporation, dated as of July 24, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 5

View Full Filing

View this 8-K filing on SEC EDGAR